Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gottlieb

Showing results (321-330 of 609) with videos related to

Pageof 61
Sort By:
Journal of Drugs in Dermatology : JDD|August 13, 2015
Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 TrialsAlice B Gottlieb, Richard G Langley, Sandra Philipp, et al.
Advances in Therapy|September 2, 2021
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b TrialAlice B Gottlieb, Richard B Warren, Matthias Augustin, et al.
Journal of the American Academy of Dermatology|October 3, 2006
Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patientsRama Malaviya, Yvonne Sun, Jennifer K Tan, et al.
Journal of the American Academy of Dermatology|August 23, 2000
Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasisJ G Krueger, I B Walters, M Miyazawa, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 8, 2014
Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trialC Paul, K Reich, A B Gottlieb, et al.
Journal of Cutaneous Pathology|October 1, 1996
Modulation of epidermal differentiation, tissue inflammation, and T-lymphocyte infilitration in psoriatic plaques by topical calcitriolI Lu, P Gilleaudeau, J A McLane, et al.
The Journal of Dermatological Treatment|November 10, 2006
Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' officesAlice B Gottlieb, Philip J Mease, J Mark Jackson, et al.
The Journal of Experimental Medicine|November 1, 1978
Ia-bearing T lymphocytes in man. Their identification and role in the generation of allogeneic helper activityS M Fu, N Chiorazzi, C Y Wang, et al.
Progress in Clinical and Biological Research|January 1, 1988
Clinical experience with crude preparations of growth factors in healing of chronic wounds in human subjectsD M Carter, A K Balin, A B Gottlieb, et al.
Dermatology and Therapy|July 11, 2023
Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support ProgramAlice B Gottlieb, Russel Burge, William N Malatestinic, et al.
Pageof 61

Showing results (321-330 of 609) with videos related to

Sort By:
Pageof 61
Journal of Drugs in Dermatology : JDD|August 13, 2015
Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 TrialsAlice B Gottlieb, Richard G Langley, Sandra Philipp, et al.
Advances in Therapy|September 2, 2021
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b TrialAlice B Gottlieb, Richard B Warren, Matthias Augustin, et al.
Journal of the American Academy of Dermatology|October 3, 2006
Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patientsRama Malaviya, Yvonne Sun, Jennifer K Tan, et al.
Journal of the American Academy of Dermatology|August 23, 2000
Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasisJ G Krueger, I B Walters, M Miyazawa, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 8, 2014
Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trialC Paul, K Reich, A B Gottlieb, et al.
Journal of Cutaneous Pathology|October 1, 1996
Modulation of epidermal differentiation, tissue inflammation, and T-lymphocyte infilitration in psoriatic plaques by topical calcitriolI Lu, P Gilleaudeau, J A McLane, et al.
The Journal of Dermatological Treatment|November 10, 2006
Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' officesAlice B Gottlieb, Philip J Mease, J Mark Jackson, et al.
The Journal of Experimental Medicine|November 1, 1978
Ia-bearing T lymphocytes in man. Their identification and role in the generation of allogeneic helper activityS M Fu, N Chiorazzi, C Y Wang, et al.
Progress in Clinical and Biological Research|January 1, 1988
Clinical experience with crude preparations of growth factors in healing of chronic wounds in human subjectsD M Carter, A K Balin, A B Gottlieb, et al.
Dermatology and Therapy|July 11, 2023
Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support ProgramAlice B Gottlieb, Russel Burge, William N Malatestinic, et al.
Pageof 61